Panasonic teams up with 7X Paralympic Champion Hannah Cockroft for Paris 2024 Paralympic Games
Celebrating the countdown to the Paris 2024 Paralympic Games, Worldwide Olympic and Paralympic Partner Panasonic joins forces with the Team England wheelchair racing 7-time Paralympic Champion and 12-time World Champion, Hannah Cockroft to promote environmental sustainability on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831059501/en/
Hannah Cockroft (Photo: Business Wire)
Since its founding, Panasonic has been committed to making positive contributions to the world and society. It has set ambitious targets to create a positive impact on environmental sustainability under its Panasonic GREEN IMPACT initiative. Hannah will join Team Panasonic as an ambassador focused on sustainability and inclusivity while receiving support from the company on her journey to her fourth Paralympic Games.
After picking up wheelchair racing at a talent day at Loughborough University in October 2007, Hannah has blazed a trail straight to legend status. As one of the most successful para-athletes in recent times, Hannah is looking forward to continuing to inspire people all over the world to embrace the Paralympic movement and celebrate inclusion.
Besides her tremendous athletic achievements, Hannah was one of 50+ Tokyo Olympians and Paralympians from 35 different countries, who took part in the Athletes of the World campaign which challenged World Leaders about the urgent need for ambitious climate action.
She is additionally using her platform to make a difference in issues beyond the sports arena, such as working with federations to reduce the use of single-use plastics. Panasonic is looking forward to working together with her on similar projects and initiatives that epitomise Panasonic’s core values of Contribution to Society, Cooperation & Team Spirit, and Untiring Effort & Improvement.
Hannah Cockroft comments, “It is a privilege to have Panasonic supporting me as I head into the Paris 2024 Paralympic Games. The backing and promotion to a wider audience will help me retain my top performing athlete position and enable me in turn to champion the need for climate change action, and increased inclusivity on a wider scale.”
Panasonic Champions the Champions
Panasonic has supported the Olympic and Paralympic Movements and their Athletes for nearly four decades. Several world-class athletes have been part of its Team Panasonic extended family. These athletes are committed to breaking barriers, improving communities, and bringing awareness to important issues such as sustainability, diversity, and inclusivity, and Hannah is no exception.
Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V. comments, “Hannah’s focus on societal change, including being a patron and ambassador for several charities that enable her to encourage others to get active, alongside her participation in the sustainability initiatives, embodies the spirit of Team Panasonic.
We are proud to welcome her to the Team Panasonic family and have her be part of our team to shine a light on global climate change initiatives and innovations that tackle the world’s most pressing environmental problems.”
For more information about Panasonic GREEN IMPACT vision visit: https://www.panasonic.com/uk/corporate/sustainability.html
For more information about Panasonic as a Worldwide Olympic and Paralympic Partner visit: Panasonic Official Olympic & Paralympic Website| Panasonic Holdings
About the Panasonic Group
Founded in 1918, and today a global leader in developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, industry, communications, and energy sectors worldwide, the Panasonic Group switched to an operating company system on April 1, 2022 with Panasonic Holdings Corporation serving as a holding company and eight companies positioned under its umbrella. The Group reported consolidated net sales of 8,378.9 billion yen (ca. 59.4 billion Euro) for the year ended March 31, 2023.
To learn more about the Panasonic Group, please visit: https://holdings.panasonic/global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831059501/en/
Contact information
Tanya Houston, Wildwood Plus, tanya.houston@wildwoodplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom